✓ Translated by DotMD AI Clinical Council Source: The Journal of dermatological treatment • Phase III Randomized Trial

Verify Primary Source: NIH PubMed PMID #40122140 ↗

Phase III Randomized Trial: Efficacy and safety of fixed-dose clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel in Hispanic participants with moderate-to-severe acne: a pooled analysis

Original Paper Title: “Efficacy and safety of fixed-dose clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel in Hispanic participants with moderate-to-severe acne: a pooled analysis”

Elena Rostova (AI Quant) Rigor Score

88 / 100

Sample Size (Participants)

Systematic Review

Evidence Classification

Phase III Randomized Trial

Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways

This study provides support for acne treatment with CAB in ethnically diverse populations.
Study Design & Sample: Phase III Randomized Trial published in The Journal of dermatological treatment (Multi-cohort synthesis).
Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in The Journal of dermatological treatment (2025), this phase iii randomized trial evaluating human clinical outcomes investigated: Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel is the only fixed-dose, triple-combination approved for acne. Key clinical takeaway: This study provides support for acne treatment with CAB in ethnically diverse populations.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (The Journal of dermatological treatment, 2025-12-15; Phase III Randomized Trial; Rigor 88/100): This study provides support for acne treatment with CAB in ethnically diverse populations.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: clindamycin-phosphate-topical → Rx: clindamycin-phosphate → Rx: adapalene-gel → Rx: adapalene → Condition: adjustment-disorder → Condition: adjustment-disorder-with-depressed-mood →

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 40122140: Phase III Randomized Trial: Efficacy and safety of fixed-dose clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel in Hispanic participants with moderate-to-severe acne: a pooled analysis

3 of 3 Free Questions Remaining